Janet H Kim, MD
Internal Medicine · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
- Since medical school
- 20 years
- Yale University School of Medicine, 2006
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kim’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A101879 · Current
Licensed to practise in California · since 2007 · expires 2027-02-28 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Infectious Disease
- American Board of Internal Medicine - Internal Medicine
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$16,471
Medicare paid this office $16,471 for 76 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 40 | $4,578 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $4,485 | $71 |
| Return visit (30+ min) | 22 | $4,157 | $82 |
Who their Medicare patients are
76 Original Medicare patients in 2024. Average age 69 · Under 65 29% · Women 36% · Also on Medicaid 83% · Health risk score 3.38. Sicker patients than 9 in 10 peers; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 75% · Diabetes 59% · Heart failure 43% · Chronic kidney disease 39% · Depression 37% · Atrial fibrillation 36% · Coronary heart disease 34% · COPD 24% · Dementia 22% · Stroke 22% · Cancer 18%.
The office billed $132,613, Medicare allowed $22,002 and paid $16,471; for 200 services of 9 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 76 | 200 | 69 | 3.38 | $132,613 | $16,471 |
| 2023 | 65 | 160 | 68 | 3.88 | $99,886 | $13,094 |
| 2022 | 61 | 165 | 68 | 3.26 | $121,881 | $13,664 |
| 2021 | 61 | 185 | 67 | 2.93 | $116,285 | $15,749 |
| 2020 | 80 | 240 | 66 | 3.78 | $156,602 | $18,063 |
| 2019 | 73 | 171 | 66 | 3.91 | $116,226 | $14,164 |
| 2018 | 68 | 193 | 66 | 3.88 | $107,362 | $14,631 |
| 2017 | 56 | 195 | 66 | 3.89 | $108,020 | $13,603 |
| 2016 | 66 | 223 | 63 | 3.56 | $88,048 | $15,432 |
| 2015 | 52 | 130 | 60 | 2.94 | $31,129 | $8,635 |
| 2014 | 84 | 181 | 66 | 2.17 | $47,206 | $11,990 |
| 2013 | 23 | 35 | 67 | 2.09 | $7,850 | $2,061 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,010 | $73 |
| Return visit (30+ min) | 20 | $2,857 | $82 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,690 | $122 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $1,952 | $59 |
| Long return visit (40+ min) | 12 | $1,729 | $133 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $491 | $45 |
2022: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,595 | $74 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,924 | $135 |
| Return visit (30+ min) | 14 | $3,016 | $77 |
| Telephone medical discussion with physician, 11-20 minutes | 12 | $1,113 | $51 |
2021: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $4,795 | $81 |
| Return visit (30+ min) | 18 | $3,528 | $88 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,536 | $149 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,888 | $61 |
2020: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $7,919 | $74 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 32 | $4,642 | $141 |
| Return visit (30+ min) | 24 | $2,513 | $57 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,269 | $45 |
2019: 4 services
| Return visit (30+ min) | 39 | $5,116 | $72 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,603 | $124 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,983 | $66 |
| Long return visit (40+ min) | 17 | $1,723 | $101 |
2018: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $4,576 | $64 |
| Return visit (30+ min) | 30 | $3,893 | $65 |
| Long return visit (40+ min) | 15 | $1,596 | $100 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 16 | $1,269 | $79 |
2017: 3 services
| Return visit (30+ min) | 36 | $5,519 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $4,085 | $63 |
| Long return visit (40+ min) | 13 | $1,256 | $90 |
2016: 6 services
| Return visit (30+ min) | 32 | $5,011 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $3,907 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,722 | $91 |
| Long return visit (40+ min) | 11 | $1,068 | $97 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $1,049 | $87 |
| Short return visit (20+ min) | 12 | $581 | $45 |
2015: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $3,343 | $63 |
| Return visit (30+ min) | 14 | $2,169 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,425 | $119 |
2014: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $5,060 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,704 | $122 |
| Return visit (30+ min) | 24 | $1,370 | $53 |
Medicaid work
$5,445 in 2024
Medicaid paid $5,445 for 573 billed services this clinician did in 2024, up to 31 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 118 | $1,993 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 67 | $1,848 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 145 | $1,603 |
| Medication list documented in medical record (COA) | 125 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 54 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 64 | $0 |
| 2024 | 573 | 6 | 31 | $5,445 |
| 2023 | 304 | 4 | 23 | $3,780 |
| 2022 | 195 | 3 | 23 | $3,258 |
| 2021 | 242 | 2 | 28 | $5,395 |
| 2020 | 319 | 3 | 25 | $5,281 |
| 2019 | 261 | 3 | 25 | $5,287 |
| 2018 | 436 | 4 | 28 | $5,094 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 112 | $1,474 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 121 | $1,186 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 36 | $713 |
| SBSQ HOSPITAL IP/OBS CARE SF/LOW MDM 25 MINUTES | 35 | $406 |
2022
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 61 | $1,721 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 118 | $1,357 |
| Return visit (30+ min) | 16 | $181 |
2021
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 164 | $3,063 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 78 | $2,332 |
2020
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 240 | $4,269 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 39 | $607 |
| Return visit (30+ min) | 40 | $405 |
2019
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 136 | $3,181 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 67 | $2,074 |
| Return visit (30+ min) | 58 | $32 |
2018
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 139 | $2,337 |
| Return visit (30+ min) | 251 | $1,847 |
| 1ST HOSPITAL IP/OBS CARE MODERATE MDM 55 MINUTES | 31 | $648 |
| IP/OBS CONSLTJ NEW/EST PT LOW MDM 45 MINUTES | 15 | $262 |
Drugs they prescribed that Part D paid
$270,656
Pharmacies billed $270,656 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 360) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
232 generic and 128 brand-name prescriptions · $270,656 in drug cost · 77 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dovato | 48 | $120,413 | $2,509 |
| Biktarvy | 25 | $90,743 | $3,630 |
| Pifeltro | 24 | $32,647 | $1,360 |
| Anoro Ellipta | 11 | $4,556 | $414 |
| Ceftazidime | 16 | $859 | $54 |
See all 9 drugs
| Dovato | 48 | $120,413 | $2,509 |
| Biktarvy | 25 | $90,743 | $3,630 |
| Pifeltro | 24 | $32,647 | $1,360 |
| Anoro Ellipta | 11 | $4,556 | $414 |
| Ceftazidime | 16 | $859 | $54 |
| Acyclovir | 12 | $122 | $10 |
| Atorvastatin | 48 | $98 | $2 |
| Chlorthalidone | 15 | $81 | $5 |
| Losartan | 13 | $32 | $2 |
Year by year
| 2024 | 360 | 24 | 0% (0) | 36% | $270,656 |
| 2023 | 296 | 24 | 0% (0) | None | $299,604 |
| 2022 | 340 | 26 | None | None | $382,094 |
| 2021 | 352 | 26 | 0% (0) | 44% | $397,645 |
| 2020 | 411 | 30 | None | 34% | $288,872 |
| 2019 | 283 | 26 | 0% (0) | 37% | $234,837 |
| 2018 | 265 | 33 | 0% (0) | None | $153,051 |
| 2017 | 311 | 33 | 7% (22) | 37% | $150,531 |
| 2016 | 199 | 27 | 18% (36) | 28% | $54,320 |
| 2015 | 310 | 54 | 11% (35) | None | $144,556 |
| 2014 | 720 | 143 | 8% (56) | None | $53,948 |
| 2013 | 145 | 56 | 19% (27) | None | $8,645 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 12 drugs
| Biktarvy | 25 | $98,199 | $3,928 |
| Dovato | 21 | $49,803 | $2,372 |
| Triumeq | 13 | $31,499 | $2,423 |
| Tivicay | 13 | $30,755 | $2,366 |
| Prezista | 13 | $30,143 | $2,319 |
| Pifeltro | 21 | $29,732 | $1,416 |
| Emtricitabine | 13 | $5,656 | $435 |
| Ritonavir | 13 | $846 | $65 |
| Doxycycline Monohydrate | 11 | $580 | $53 |
| Atorvastatin | 34 | $273 | $8 |
| Chlorthalidone | 12 | $62 | $5 |
| Fenofibrate | 13 | $61 | $5 |
2022: 16 drugs
| Biktarvy | 26 | $99,106 | $3,812 |
| Cresemba | 18 | $93,879 | $5,216 |
| Dovato | 25 | $54,542 | $2,182 |
| Pifeltro | 26 | $34,460 | $1,325 |
| Tivicay | 12 | $25,929 | $2,161 |
| Prezista | 12 | $25,370 | $2,114 |
| Emtricitabine | 13 | $5,656 | $435 |
| Ritonavir | 13 | $846 | $65 |
| Sulfamethoxazole-Trimethoprim | 19 | $547 | $29 |
| Doxycycline Monohydrate | 15 | $387 | $26 |
| Atorvastatin | 33 | $234 | $7 |
| Pravastatin | 13 | $230 | $18 |
| Chlorthalidone | 13 | $83 | $6 |
| Fenofibrate | 12 | $79 | $7 |
| Losartan | 13 | $59 | $5 |
| Amlodipine Besylate | 13 | $30 | $2 |
2021: 14 drugs
| Biktarvy | 34 | $113,720 | $3,345 |
| Cresemba | 16 | $72,917 | $4,557 |
| Tivicay | 31 | $55,094 | $1,777 |
| Triumeq | 16 | $46,737 | $2,921 |
| Descovy | 18 | $28,834 | $1,602 |
| Dovato | 12 | $27,388 | $2,282 |
| Prezista | 13 | $25,397 | $1,954 |
| Doxycycline Monohydrate | 18 | $835 | $46 |
| Atorvastatin | 38 | $191 | $5 |
| Fenofibrate | 12 | $115 | $10 |
| Pravastatin | 12 | $90 | $8 |
| Losartan | 13 | $75 | $6 |
| Amlodipine Besylate | 13 | $46 | $4 |
| Hydrochlorothiazide | 13 | $23 | $2 |
2020: 18 drugs
| Biktarvy | 22 | $71,939 | $3,270 |
| Tivicay | 35 | $58,781 | $1,679 |
| Triumeq | 20 | $53,377 | $2,669 |
| Descovy | 23 | $35,939 | $1,563 |
| Prezista | 12 | $22,381 | $1,865 |
| Emtriva | 12 | $6,805 | $567 |
| Ritonavir | 12 | $781 | $65 |
| Doxycycline Monohydrate | 21 | $633 | $30 |
| Atorvastatin | 34 | $177 | $5 |
| Losartan | 13 | $109 | $8 |
| Bupropion Xl | 11 | $97 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $86 | $7 |
| Benazepril | 12 | $79 | $7 |
| Pravastatin | 13 | $71 | $5 |
| Amlodipine Besylate | 13 | $59 | $5 |
| Atenolol | 13 | $41 | $3 |
| Omeprazole | 11 | $29 | $3 |
| Hydrochlorothiazide | 13 | $25 | $2 |
2019: 8 drugs
| Tivicay | 30 | $52,641 | $1,755 |
| Triumeq | 16 | $45,268 | $2,829 |
| Odefsey | 11 | $29,654 | $2,696 |
| Prezista | 13 | $23,094 | $1,776 |
| Doxycycline Monohydrate | 19 | $1,116 | $59 |
| Amlodipine Besylate | 15 | $97 | $6 |
| Atorvastatin | 15 | $68 | $5 |
| Atenolol | 12 | $38 | $3 |
2018: 8 drugs
| Tivicay | 26 | $43,555 | $1,675 |
| Descovy | 14 | $22,784 | $1,627 |
| Prezista | 13 | $21,577 | $1,660 |
| Norvir | 13 | $3,771 | $290 |
| Doxycycline Monohydrate | 13 | $302 | $23 |
| Omeprazole | 13 | $89 | $7 |
| Atorvastatin | 15 | $85 | $6 |
| Pravastatin | 12 | $80 | $7 |
2017: 12 drugs
| Triumeq | 23 | $59,738 | $2,597 |
| Tivicay | 12 | $18,694 | $1,558 |
| Prezista | 12 | $17,832 | $1,486 |
| Itraconazole | 11 | $5,430 | $494 |
| Norvir | 15 | $3,901 | $260 |
| Hydrocodone-Acetaminophen | 13 | $193 | $15 |
| Sulfamethoxazole-Trimethoprim | 16 | $168 | $10 |
| Amlodipine Besylate | 23 | $146 | $6 |
| Ciprofloxacin | 12 | $139 | $12 |
| Atorvastatin | 19 | $120 | $6 |
| Pravastatin | 12 | $89 | $7 |
| Benazepril | 12 | $43 | $4 |
2016: 4 drugs
| Norvir | 15 | $3,849 | $257 |
| Fentanyl | 11 | $455 | $41 |
| Sulfamethoxazole-Trimethoprim | 23 | $441 | $19 |
| Hydrocodone-Acetaminophen | 25 | $355 | $14 |
2015: 7 drugs
| Reyataz | 12 | $14,934 | $1,244 |
| Invanz | 14 | $8,512 | $608 |
| Meropenem | 14 | $6,053 | $432 |
| Norvir | 12 | $3,050 | $254 |
| Doxycycline Hyclate | 14 | $1,709 | $122 |
| Hydrocodone-Acetaminophen | 22 | $432 | $20 |
| Sulfamethoxazole-Trimethoprim | 17 | $248 | $15 |
2014: 14 drugs
| Ventolin Hfa | 17 | $765 | $45 |
| Atorvastatin | 11 | $759 | $69 |
| Hydrocodone-Acetaminophen | 31 | $755 | $24 |
| Gabapentin | 32 | $616 | $19 |
| Levothyroxine | 19 | $377 | $20 |
| Fosinopril | 17 | $358 | $21 |
| Simvastatin | 33 | $338 | $10 |
| Metformin | 28 | $300 | $11 |
| Finasteride | 11 | $229 | $21 |
| Losartan | 18 | $206 | $11 |
| Amlodipine Besylate | 34 | $200 | $6 |
| Benazepril | 13 | $126 | $10 |
| Metoprolol | 19 | $124 | $7 |
| Atenolol | 17 | $95 | $6 |
2013: 1 drug
| Hydrocodone-Acetaminophen | 25 | $485 | $19 |
Money from drug and device companies
$25 in 2024
A payment is not proof that care is biased.
| Theratechnologies | Egrifta | $25 | 1 payment
|
See the published payment
| Theratechnologies | Meals · 2024-10-28 | Egrifta | $25 |
Professional record
- NPI
- 1205015708
- Licence
- CA A101879California A101879: Current · expires 2027-02-28
- Trained
- Yale University School of Medicine, 2006 · 20 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2400 Moorpark Ave, Suite 316, San Jose, CA, 95128
- NPI first listed
- 2007-10-31
- NPI last updated
- 2014-07-03
This is when the NPI record was last certified, not a medical board exam.